RSC Advances | 2021

Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells

 

Abstract


Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D.

Volume 11
Pages 5265-5265
DOI 10.1039/D1RA90049H
Language English
Journal RSC Advances

Full Text